Cardiac Ablation Market By Product (Radiofrequency (RF), Ablators, Electrical Ablators, Cryoablation Devices, Ultrasound Ablators), By Approach (Open/Surgical, Catheter-Based), By End-use Global Opportunity Analysis and Industry Forecast, 2022-2031
- Published Date: January, 2024 | Report ID: CLS-2095 | No of pages: 250 | Format:
The market was valued at $3.80 billion in 2022. It is projected to grow at a CAGR of 14.3% from 2023 to 2031 and reach more than $12.62 billion by the end of 2031.
Analysts’ Viewpoint by Cognate Lifesciences
According to industry analysts, the global, the paradigm change toward less invasive cardiac ablation therapies has been a key driver of market expansion. These procedures, which are distinguished by lower morbidity, faster recovery periods, and improved patient comfort, have gained worldwide adoption. As technological breakthroughs continue to seamlessly surgical techniques, their adoption is likely to rise dramatically which is propelling the market growth in the forecasted period.
The growth and upgrading of healthcare infrastructures, particularly in developing countries, has made sophisticated cardiac care treatments more accessible. Investments in cutting-edge cardiac care facilities, in addition to training programs for healthcare workers, have aided in the widespread adoption of cardiac ablation business activities.
Cardiac Ablation Market Overview
The global cardiac ablation market plays a key role in solving medical gaps related to heart diseases. With an increasing number of patients seeking alternative therapy options, cardiac ablation is emerging as a feasible and effective therapeutic method. Market growth and diversification will continue to accelerate as healthcare professionals and patients increasingly recognize the clinical efficacy and advantages of ablation therapy. Modernization and development of cardiac care facilities, particularly in emerging markets, have accelerated market growth and penetration. Investments in modern equipment, infrastructure enhancements, and training programs for healthcare professionals have made complex cardiac ablation procedures more accessible, promoting market expansion and patient access.
Robotic-assisted catheter navigation technologies are gaining popularity in the cardiac ablation sector, allowing for more procedural control, flexibility, and accuracy. These robotic systems, which are outfitted with enhanced imaging and navigation capabilities, allow for remote catheter manipulation, accurate lesion generation, and optimum tissue contact, resulting in increased procedure effectiveness and operator efficiency. The integration of digital health technologies, including telemedicine, remote monitoring, and digital therapies, is improving cardiac ablation service delivery, care coordination, and resource usage. These digital interventions provide seamless communication, data sharing, and collaborative decision-making among healthcare professionals, resulting in increased operational efficiency, patient-centric care delivery, and value-based results.
New product launches to flourish in the market
The cardiac ablation market is expected to see several new product launches in the coming years. Some of the key product launches expected in the cardiac ablation market are:
- Cardiac Ablation Products Without Fluoroscopy- Biosense Webster, a medical device manufacturer, FDA in the U.S. have received approval for zero fluoroscopy workflow operations from the U.S. Food and Drug Administration (FDA). These goods are approved for use in a workflow technique that excludes fluoroscopy. A common imaging method is fluoroscopy, which creates moving, real-time images of a patient's interior anatomy using X-rays. Biosense Webster aims for FDA approval for a workflow that eliminates the need for fluoroscopy to offer medical practitioners an alternative that might lessen radiation exposure to patients and staff.
OCTARAY Mapping Catheter- In September 2022, Johnson & Johnson subsidiary Biosense Webster has introduced its TrueFREEDOM Technology-equipped OCTARay Mapping Catheter. By improving accuracy and efficiency during cardiac mapping procedures, the new catheter seeks to strengthen the company's prominence in the cardiac medical device industry.
Segment Overview:
By Product: The cardiac ablation market is divided into radiofrequency (RF) ablators, electrical ablators, cryoablation devices, and ultrasound ablators. The dominating segment of the cardiac ablation market is radiofrequency (RF) ablators. This segment is expected to account for the largest share of the market in the coming years. The growth of this segment is being driven by the technological developments in RF ablation systems, including device-reducing staffing, improved energy delivery mechanisms, and better control systems, which are prompting procedure safety, effectiveness, and patient outcomes. The rising frequency of chronic illnesses, including cardiovascular disease, cancer, and pain management issues, is driving the demand for effective therapeutic approaches such as RF ablation. Factors such as aging populations, poor physical activity, and rising healthcare costs are all contributing to the growing worldwide burden of chronic illnesses, demanding innovative and minimally intrusive treatment approaches. The fastest-growing segment of the cardiac ablation market is electrical ablators. This segment is expected to grow at a CAGR of 13.8% from 2023 to 2031. The growth of this segment is being driven by advances in electrophysiology, a growing number of cardiac arrhythmias, and the need to find effective therapeutic therapies. Electrical ablators in cardiac applications are becoming more prevalent as a result of advancements in energy delivery systems, catheter designs, and surgical procedures.
By Approach: The cardiac ablation market is divided into catheter-based and open/surgical. The dominating segment of the Cardiac Ablation market is catheter-based leading to the highest market share. The use of cutting-edge technologies, such as robotic navigation, real-time imaging, and 3D mapping systems, has substantially enhanced procedure accuracy and performance. Improved patient outcomes result from these advances' enhanced visualization and precision, which provide doctors more authority. The fastest-growing segment of the Cardiac Ablation market is open/surgical. The open or surgical segment continues to be an essential component in the ever-changing cardiac ablation business, providing customized therapies for patient demographics and circumstances. Although catheter-based methods have become more popular due to their less intrusive nature, the open/surgical market still plays a crucial role in managing cardiac arrhythmias by addressing specific problems and offering customized treatments.
By Application: The cardiac ablation market is segmented into cardiac arrhythmia, atrial fibrillation (AF), tachycardia, and open surgery. The atrial fibrillation segment is expected to dominate the cardiac ablation market in the coming years. AF is a widespread cardiac arrhythmia, and catheter ablation has become a conventional treatment option for specific types of AF, leading to the highest market share. The increasing prevalence of AF, innovations in ablation technology, and increased use of catheter ablation techniques have fuelled the AF segment's rise. The tachycardia segment is expected to be the fastest-growing segment of the cardiac ablation market in the coming years. The tachycardia segment is expanding due to increased demand for less invasive ablation methods. Minimally invasive techniques, which are characterized by lower morbidity, less time in the hospital, and improved patient comfort, appeal to both healthcare professionals and patients, promoting acceptance and market expansion in the tachycardia category.
By End-use: The cardiac ablation market is segmented into hospitals, ambulatory surgical centers, cardiac centers, and others. The dominating segment of the cardiac ablation market is hospitals leading to the highest market share. Hospitals are essential to patient management since they are the primary care providers for cardiac ablation operations. The foundation of cardiac care delivery is formed by their infrastructure, knowledge, and resources, which ensure prompt interventions, optimal results, and thorough post-procedural care. The hospitals promotes treatment strategy innovation and procedural excellence when combined with continuous training and professional development. The cardiac centers segment is expected to be the fastest-growing segment of the cardiac ablation market in the coming years. A wider range of cardiac arrhythmias and complex situations can be treated by cardiac centers due to the development of novel ablation methodologies, alternative energy sources, and next-generation technologies. Therapeutic approaches can be customized based on patient profiles at cardiac centers, improving treatment efficacy and outcomes. This is made possible by advancements in precision medicine, genomics, and personalized diagnostics.
By Region:
The North American region is projected to maintain its dominance in the global cardiac ablation market. In 2022, it held the largest revenue share of over 43%. The region's focus on tailored treatment algorithms, patient-centered care models, and holistic care delivery improves treatment efficacy, encourages patient involvement, and propels market expansion. Customized therapeutic approaches, in conjunction with extensive patient education and assistance programs, maximize treatment results and position North America as an industry leader in the delivery of quality cardiac care which is anticipated to propel the market growth in forecasted period.
The Asia Pacific region is poised to experience the most rapid growth in the global cardiac ablation market during the forecast period. The region's rapidly developing healthcare infrastructure, which includes cutting-edge hospitals, cardiac care clinics, and advanced diagnostic labs, is contributing to the increased use of cardiac ablation treatments. Heart arrhythmias are becoming more common in the Asia Pacific region; this upward trend is linked to changing lifestyle habits, an increase in age-related illnesses, and an epidemiological change. This increasing rate of illness burden highlights the need for improved therapeutic approaches, which is driving the use of cardiac ablation as a preferred mode of treatment.
Competitive analysis and profiles of the major players in the cardiac ablation market, such as Abbott Laboratories, Medtronic, Biosense Wenster (Johnson & Jaohnson), Angidynamics, Boston Scientific Corporation, Articure, Japan Lifeline, MicroPort Scientific Corporation, Catheter Precision, Inc., and Stereotaxis, Inc.
Major players have adopted product launch and acquisition as key developmental strategies to improve the product portfolio of the cardiac ablation market.
Market Scope and Structure Analysis
|
Report Metric |
Details |
|
Market Size Available for Years |
2021–2031 |
|
Base Year Considered |
2022 |
|
Forecast Period |
2023–2031 |
|
Forecast Unit |
Value (USD) |
|
Segments Covered |
By product, approach, application, end-use, and Region |
|
Regions Covered |
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa |
|
Companies Covered |
|
Key Segments Covered
Product
- Radiofrequency (RF) ablators
- Electrical ablators
- Cryoablation devices
- Ultrasound ablators
Approach
- Catheter-based
- Open/surgical
Application
- Cardiac arrhythmia
- Atrial fibrillation (AF)
- Tachycardia
- Open surgery
End-use
- Hospitals
- Cardiac centers
- Ambulatory surgical centers
- Others
Region
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Israel
Rest of Middle East & Africa